Last year saw an upturn in new drug approvals, the end of patent protection for the world's top-selling drug, continued regulatory negotiations and more.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
10 February 2012
Daclatasvir was originally misidentified as an NS5A protease inhibitor, when it is an NS5A replication complex inhibitor. This has been corrected in the online version of the article.
Rights and permissions
About this article
Cite this article
Mullard, A. 2011 in reflection. Nat Rev Drug Discov 11, 6–8 (2012). https://doi.org/10.1038/nrd3643
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3643
This article is cited by
-
Erratum: 2011 in reflection
Nature Reviews Drug Discovery (2012)